| Expression pattern: |
UP |
| Associated gene: |
MECP2, AGO2 |
| Associated microRNA: |
miR-1324 |
| Biological function: |
promotes sorafenib resistance, promotes proliferation, inhibits sorafenib-induced apoptosis, and decreases G0/G1 arrest in HCC cells |
| Molecular mechanism: |
ceRNA mechanism: circFOXM1 sponges miR-1324 to relieve repression of MECP2, increasing MECP2 expression and promoting sorafenib resistance |
| Biological pathway or process: |
ceRNA regulation (promotes); proliferation (promotes); apoptosis (inhibits); cell cycle (promotes); drug resistance (promotes) |
| Detected method: |
Q
S
|
| Validation methods: |
RNA-seq; RNase R Treatment; RT-qPCR; Actinomycin D / DRB Stability Assay; Nuclear-Cytoplasmic Fractionation; RIP (RNA Immunoprecipitation); RNA Pull-Down; Luciferase Reporter Assay; Transfection; CCK8; Cell Cycle Assay; Annexin V/PI Flow Cytometry; Western Blot; Clinical Sample Validation; Survival Analysis; Bioinformatics Analysis |
| Clinical significance: |
High circFOXM1 expression is higher in tumor vs adjacent tissues and in sorafenib-resistant vs sorafenib-sensitive tissues; circFOXM1high is associated with larger tumors, microvascular invasion, advanced stage, and worse prognosis |
| Description: |
circFOXM1 is up-regulated in HCC, especially in sorafenib-resistant tissues/cells, and its high level correlates with worse prognosis. Functionally, circFOXM1 promotes sorafenib resistance and malignant phenotypes by acting as a ceRNA that sponges miR-1324 to increase MECP2 expression. |
| Confidence score: |
0.8625 |